A clinical trial reported that isoquercetin at a dose of 1 g day-1 for 56 days significantly reduced D-dimer, P-selectin, and platelet-dependent fibrin production in cancer patients compared to placebo, suggesting that supplementation with isoquercetin prevents hypercoagulability and thrombosis in cancer patients (Manjunath and Thimmulappa, 2022). This evidence concerns the gene SELP and cancer.